GlassScriptPhysician profile
Edward G Brooks
NPI 1134211998
$2,781.84
in general payments reported to CMS, 2019-2025
24 companies · $486 in 2025
The $486 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $869 · 2020: $23.41 · 2021: $255 · 2022: $523 · 2023: $80.94 · 2024: $544 · 2025: $486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,086 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,086.40 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $563.93 | 2019-2024 | |
| Genzyme Corporation | $348.66 | 2022-2025 | |
| Optinose US, INC. | $154.31 | 2022 | |
| Alk-Abello, INC | $141.81 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $133.62 | 2023-2025 | |
| Mylan Specialty L.P. | $124.99 | 2024 | Yupelri |
| Gilead Sciences, INC. | $124.99 | 2019 | |
| Genentech USA, INC. | $124.99 | 2024 | Xolair |
| Shire North American Group INC | $122.08 | 2019 | |
| Bioverativ Therapeutics INC. | $119.99 | 2019 | |
| Alcresta Therapeutics, INC. | $118.52 | 2025 | Relizorb |
| Novartis Pharmaceuticals Corporation | $116.74 | 2019 | |
| Csl Behring | $108.13 | 2022-2025 | Hizentra |
| Glaxosmithkline, LLC. | $99.99 | 2019 | |
| Pfizer INC. | $98.78 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $48.19 | 2023-2025 | |
| Gc Biopharma USA, INC. | $40.74 | 2025 | Alyglo |
| Grifols USA, LLC | $38.56 | 2023-2025 | Xembify |
| Greer Laboratories, INC. | $30.85 | 2024 | Oralair |
| Takeda Pharmaceuticals U.S.A., INC. | $29.25 | 2025 | Cuvitru |
| Syndax Pharmaceuticals, INC. | $27.71 | 2025 | |
| Ionis Pharmaceuticals, INC. | $25.00 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $21.40 | 2022 | |
| Amgen INC. | $18.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.